MedTrace Logo

Safety and Efficacy of SWK002 in Patients With D2T-Rheumatoid Arthritis

NCT06503237 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2025-02-28

No results posted yet for this study

Summary

This is an open label, single-site, dose-escalation study in up to 18 participants with refractory rheumatoid arthritis. This study aims to evaluate the safety and efficacy of the treatment with Anti-CD19 CART.

Conditions

Interventions

DRUG

Anti-CD19 CART cells will be given IV at split doses.

Split intravenous infusion of Anti-CD19 CART cells of (Dose escalating infusion of 1 - 6 x10\^6 CART cells/kg).

Sponsors & Collaborators

  • The First Affiliated Hospital of University of Science and Technology of China

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-11-09
Primary Completion
2026-03-31
Completion
2026-03-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06503237 on ClinicalTrials.gov